<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>FDA-Approved Drugs Protect Mammalian Neurons <br /> from Glucose Toxicity Slow Aging Dependent Cbp <br /> and Protect Against Proteotoxicity <br /> Alex Lublin1, Fumiko Isoda1, Harshil Patel1, Kelvin Yen2, <span id='am-68' about='obo:NCBITaxon_1191644' typeof='obo:NCBITaxon_34667 obo:NCBITaxon_79514 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_71528 obo:NCBITaxon_41084 obo:NCBITaxon_33154 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_294789 obo:NCBITaxon_197563 obo:NCBITaxon_41088 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_50557 obo:NCBITaxon_7041'><span id='am-69'  ></span><span id='am-70' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-71' property="rdfs:label" content="Linda" datatype="xsd:string"></span><span id='am-72' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Linda</span> Nguyen1, Daher Hajje1, Marc Schwartz1, <br /> Charles Mobbs1* <br /> 1 Fishberg Center Neurobiology, Mount Sinai School Medicine, New York, New York, United States America, 2 Program Gene Function Expression, <br /> University Massachusetts Medical School, Worcester, Massachusetts, United States America <br />  <br />  <br />  <br />     Abstract <br />     Screening library drugs known safety profiles humans yielded 30 drugs reliably protected mammalian neurons <br />     glucose toxicity. Subsequent screening demonstrated 6 30 drugs increase lifespan C. elegans: caffeine, <br />     ciclopirox olamine, tannic acid, acetaminophen, bacitracin, baicalein. Every drug significantly reduced age-dependent <br />     acceleration mortality rate. These protective effects blocked RNAi inhibition cbp-1 adults only, also <br />     blocks protective effects dietary restriction. Only 2 drugs, caffeine tannic acid, exhibited similar dependency DAF- <br />     16. Caffeine, tannic acid, bacitracin reduced pathology transgenic model proteotoxicity associated with <br />     Alzheimer&#8217;s disease. These results support key role glucose toxicity driving age-related pathologies CBP- <br />     1 protection age-related pathologies. These results provide novel lead compounds known safety profiles in <br />     human treatment age-related diseases, including Alzheimer&#8217;s disease diabetic complications. <br />  <br />   Citation: Lublin A, Isoda F, Patel H, Yen K, Nguyen L, et al. (2011) FDA-Approved Drugs Protect Mammalian Neurons Glucose Toxicity Slow Aging <br />   Dependent Cbp Protect Against Proteotoxicity. PLoS ONE 6(11): e27762. doi:10.1371/journal.pone.0027762 <br />   Editor: Giovambattista Pani, Catholic University Medical School, Italy <br />   Received August 30, 2011; Accepted October 24, 2011; Published November 16, 2011 <br />   Copyright: &#223; 2011 Lublin et al. <span id='am-53' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-54' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-56'  ></span><span id='am-57' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>This</span> open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Funding: This work funded National Institutes Health, grant 1R01HD060914-01. The funders role study design, <span id='am-73' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-74' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-76' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-77'  ></span>data</span> collection and <br />   analysis, decision publish, preparation manuscript. <br />   Competing Interests: The authors declared competing interests exist. <br />   * E-mail: charles.mobbs@mssm.edu <br />  <br />  <br />  <br /> Introduction                                                                     glucose utilization <span id='am-1' about='obo:NCBITaxon_3554' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_3563 obo:NCBITaxon_91827 obo:NCBITaxon_71240 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_3524 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_3193'><span id='am-2'  ></span><span id='am-3' property="oboInOwl:hasRelatedSynonym" content="Beta L. 1753" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-6' property="rdfs:label" content="Beta" datatype="xsd:string"></span>beta</span> oxidation [6]. These other <br />                                                                                  observations [7,8] suggest drugs protect glucose <br />     A promising implication aging research interventions              toxicity plausibly mimic protective effects of <br /> directed fundamental processes aging mimic broad                   dietary restriction, including reduction age-dependent <br /> protective effects dietary restriction age-related pathol-            acceleration mortality rate [9]. We hypothesized the <br /> ogies (e.g., activation sirtuins resveratrol [1]). Furthermore,            protective effects drugs depend CBP-1 and <br /> the discovery specific drugs increase lifespan led new               possibly DAF-16 [6]. <br /> insight role targets drugs play aging                    To address hypothesis developed high-throughput <br /> process. For example, screening drugs variety functional               screen discover drugs protect glucose toxicity in <br /> classes structure led discovery anti-convulsant                  mammalian neurons, since, indicated above, growing evidence <br /> drugs extend lifespan C. elegans, supporting unexpected role               indicates neurons play key role aging protective <br /> of neuronal activity determining lifespan [2]. Similarly, screen            effects dietary restriction [10]. We focused library drugs <br /> of 88,000 compounds led discovery anti-                     established safety profiles humans, mainly drugs approved <br /> depressant drug mianserin extends lifespan C. elegans, supporting             use humans FDA, drugs most <br /> a novel role serotonin determining lifespan [3]. Other                    readily translated clinical use [11]. Drugs corroborated be <br /> studies C. elegans role <span id='am-63' about='obo:NCBITaxon_172918' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_186627 obo:NCBITaxon_186626 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_7952 obo:NCBITaxon_7953 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_32519 obo:NCBITaxon_30727 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_186634 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_7898 obo:NCBITaxon_41665 obo:NCBITaxon_32443'><span id='am-64'  ></span><span id='am-65' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-66' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-67' property="rdfs:label" content="Tor" datatype="xsd:string"></span>TOR</span> pathway determining              protective mammalian neurons screened activity <br /> lifespan [4] led discovery rapamycin extends lifespan             increase lifespan, reduce age-related acceleration mortality <br /> mice [5], crucially supporting mTOR pathway plays key                 rate, reduce pathology transgenic model proteotoxi- <br /> role mammalian aging providing lead compound                      city Alzheimer&#8217;s disease (CL2006) [12]. Finally, assessed if <br /> variety age-related diseases, especially <span id='am-36' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-37'  ></span><span id='am-38' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-39' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>cancer</span>.                              protective effects drugs depend DAF-16 CBP-1. <br />     We recently reported protective effects dietary <br /> restriction ablation insulin-like pathway require                     Results <br /> induction transcriptional co-activator Creb-binding protein <br /> (Cbp), expression hypothalamus mice                         Thirty drugs protect glucose toxicity in <br /> accounts 80% lifespan variance 5 strains mice                  mammalian neurons <br /> [6]. This study suggested protective effects dietary              Many lines evidence suggest glucose metabolism and <br /> restriction Cbp mediated metabolic shift away                  toxicity contribute aging [8] diabetic complications <br />  <br />  <br />        PLoS ONE | www.plosone.org                                            1                         November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                                                                                FDA-Approved Drugs Protect Aging <br />  <br />  <br /> [13]. We hypothesized drugs ameliorate                           Caffeine increases lifespan slows aging dependent <br /> glucose-induced vulnerability oxidative stress protect                  DAF-16 CBP-1 delays proteotoxicity <br /> against toxicity aging. To discover drugs developed                       To assess drugs protective aging, effects <br /> an assay assess glucose-induced toxicity neurons [14]. The                      drug lifespan assessed adult N2 C. elegans, at <br /> primary screen, utilizing dye-based assay neuronal viability,                     concentrations 0.01, 0.1, 1%. Seven thirty drugs <br /> yielded 42 drugs significantly enhanced viability 15 mM                       produced significant increases lifespan one <br /> glucose (p,0.05, .50% enhanced viability). These 42 protective                        concentration (often drugs increased lifespan concen- <br /> drugs screened using secondary assay, measuring                           tration reduced lifespan higher concentration). After the <br /> lactate dehydrogenase released medium marker cell                    initial screen indicated concentration these <br /> death. Thirty 42 drugs significantly reduced neuronal                        drugs increased lifespan, protective effects drug the <br /> death 15 mM glucose (Table 1). Dose-response curves                           optimum dose corroborated using detailed <br /> then generated drug, corroborated drugs                       analyses survival curves wild-type worms the <br /> enhanced neuronal viability 15 mM glucose presence                       Abeta transgenic model Alzheimer&#8217;s disease proteotoxicity. For <br /> oxidative stress (Table 1 Figure S1).                                             example, caffeine 0.1% increased maximum lifespan 52% <br />  <br />  <br />  <br />  <br />  Table 1. Drugs protect glucose induced hydrogen peroxide toxicity mouse primary neurocytes. <br />  <br />  <br />  Drug                                      %LDH (Mean)            %LDH (Sem) EC 50             Human dosage                        LD 50 <br />  <br />  CAFFEINE                                  26.0                   6.5           14.1           100&#8211;200 mg/4 hrs                    192 mg/kg oral <br />  CICLOPIROX OLAMINE                        17.5                   4.7           1.1            NA                                  NA <br />  TANNIC ACID                               27.1                   6.2           0.17           NA                                  1000 mg/kg oral <br />  ACETAMINOPHEN                             47.4                   8.7           8.2            90 mg/kg/day                        1944 mg/kg oral <br />  BACITRACIN                                27.1                   7.6           34.6           NA                                  .3750 mg/kg oral <br />  BAICALEIN                                 47.8                   16.1          18.6           NA                                  NA <br />  HYDRALAZINE HCl                           33.5                   14.3          92.3           7.5 mg/kg max                       173&#8211;187 mg/kg oral <br />  POTASSIUM p-AMINOBENZOATE                 15.4                   6.5           5.2            NA                                  NA <br />  AMILORIDE HCl                             23.4                   2.4           18.2           5&#8211;10 mg/day                         36&#8211;85 mg/kg oral <br />  METHACYCLINE HCl                          23.8                   5.2           53.8           8.5 mg/kg/day                       252 mg/kg IP <br />  2-THIOURACIL                              27.3                   11.2          23.6           30&#8211;60 mg/day                        2100 mg/kg oral <br />  AMINOGLUTETHIMIDE                         31.0                   13.2          32.3           250mg/6 hrs                         625 mg/kg IP* <br />  PROTHIONAMIDE                             32.0                   12.1          5.8            1000 mg/day                         1320 mg/kg oral <br />  AESCULIN                                  32.3                   7.6           44.8           100&#8211;150 mg/day                      NA <br />  PINDOLOL                                  33.6                   5.4           5.1            10&#8211;60 mg/day                        263 mg/kg oral <br />  TOLAZAMIDE                                33.6                   5.4           13.1           100&#8211;1000 mg/day                     200 mg/kg oral* <br />  BERBAMINE HCl                             35.4                   8.9           88.8           150 mg/6 hrs                        15000 mg/kg oral <br />  FENBUFEN                                  35.7                   5.3           42.6           4.285 mg/kg/8 hrs                   800 mg/kg oral <br />  BETAMETHASONE                             38.5                   11.5          62.5           .6&#8211;7.2 mg/day                       1607 mg/kg oral* <br />  BACLOFEN                                  39.0                   0.6           95.7           40&#8211;80 mg/day                        145 mg/kg oral <br />  3,5-DINITROCATECHOL                       39.8                   8.0           60.6           NA                                  500 mg/kg oral* <br />  PIPERINE                                  42.3                   8.3           69.5           10 mg/day                           514 mg/kg oral <br />  CHLORZOXAZONE                             43.1                   3.7           85.5           250&#8211;750 mg/6 hrs                    763 mg/kg oral <br />  BUSULFAN                                  43.2                   12.6          10.3           2&#8211;4 mg/kg/day                       15 mg/kg oral <br />  BITHIONOL                                 43.7                   10.6          88.0           5&#8211;25 mg/day                         7 mg/kg oral <br />  AMPROLIUM                                 44.6                   5.6           14.4           NA                                  6170 mg/kg oral* <br />  DIHYDROJASMONIC ACID                      45.3                   2.6           95.2           NA                                  NA <br />  TRANYLCYPROMINE SULFATE                   46.3                   10.2          102.5          30&#8211;60 mg/day                        30 mg/kg IP <br />  ANTIPYRINE                                49.3                   21.5          86.8           NA                                  1750 mg/kg oral <br />  SODIUM p-AMINOSALICYLATE                  56.5                   5.7           10.0           5&#8211;6 g/12 hrs                        8000 mg/kg oral <br />  ETODOLAC                                  77.7                   2.7           88.3           1000 mg/day                         94 mg/kg oral <br />  <br />  The seven drugs represent candidates positive effects C. elegans models. The remaining dugs ranked according effectiveness in <br />  comparison untreated controls (%LDH (mean)). The effective concentration culture represented &#8216;&#8216;EC 50.&#8217;&#8217; When available, normal human dosages lethal <br />  mammalian dose (LD 50) rat, unless stated otherwise, listed. Chemical formula, molecular weight, current uses drugs (Function) shown. <br />  *LD 50 performed mouse. <br />  doi:10.1371/journal.pone.0027762.t001 <br />  <br />  <br />  <br />         PLoS ONE | www.plosone.org                                              2                          November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                         FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                  Figure 1. Caffeine increased maximum median lifespan <br />                                  dependent DAF-16 CBP-1 delays toxicity a <br />                                  transgenic model Alzheimer&#8217;s disease. A. Caffeine (0.1%) <br />                                  increases maximum median lifespan (P,0.01). B. Caffeine does <br />                                  increase lifespan daf-16 inhibited RNAi. C. Caffeine does <br />                                  increase lifespan cbp-1 inhibited RNAi. D. Paralysis is <br />                                  delayed survival Abeta Tg increased 0.1% caffeine vs. <br />                                  vehicle (P,01). <br />                                  doi:10.1371/journal.pone.0027762.g001 <br />  <br />  <br />  <br />                                  (Figure 1A) (Table 3) significantly increased median <br />                                  lifespan (p,0.01 log rank Mantel-Cox test; n = 45) (Figure 1A). <br />                                  Protective effects caffeine completely blocked inhibition <br />                                  DAF-16 (Figure 1B) CBP-1 (Figure 1C) RNAi. <br />                                  Finally, 0.1% caffeine significantly delayed pathology a <br />                                  transgenic Abeta C. elegans model proteotoxicity Alzheimer&#8217;s <br />                                  disease (p,0.01; n = 30). Caffeine reduced age-dependent <br />                                  acceleration mortality rate 53%, protective effect <br />                                  blocked RNAi inhibition CBP-1 DAF-16 <br />                                  (Table 2). <br />  <br />                                  Ciclopirox increases lifespan slows aging, does <br />                                  delay proteotoxicity <br />                                     Ciclopirox olamine (0.01%), used treat dermatological fungus <br />                                  infections, increased maximum lifespan 52% (Table 3) and <br />                                  significantly increased median lifespan (p,0.01 Mantel-Cox <br />                                  log rank test; n = 45) (Figure 2A). In contrast caffeine, ciclopirox <br />                                  increased lifespan daf-16 inhibited RNAi <br />                                  (Figure 2B) (p,0.01; n = 30). Like drugs tested, cbp-1 <br />                                  inhibition RNAi blocked effect ciclopirox increase <br />                                  maximum lifespan. However, unlike drugs study, <br />                                  effect median lifespan produced ciclopirox, while <br />                                  reduced, significant (p,0.01; n = 30). Furthermore, like <br />                                  caffeine, ciclopirox reduced age-dependent acceleration mor- <br />                                  tality rate (Table 2). Interestingly, inhibition daf-16 and <br />                                  cbp-1 blocked protective effect appeared to <br />                                  unmask toxic effect ciclopirox enhance age-related <br />                                  acceleration mortality rate accompanied striking reduction <br />                                  initial mortality rate (Table 2). A similar effect observed for <br />                                  caffeine, did achieve statistical significance <br />                                  (Table 2). In contrast caffeine, ciclopirox did not <br />                                  protect pathology associated proteotoxicity <br />                                  (Figure 2D), fact 1% concentration accelerated that <br />                                  pathology (not shown). <br />  <br />                                  Tannic acid increases lifespan slows aging <br />                                  dependent DAF-16 CBP-1 delays <br />                                  proteotoxicity <br />                                      Tannic acid (0.01%), highly soluble polyphenol, increased <br />                                  maximum lifespan 59% (Table 3) significantly increased <br />                                  median lifespan (P,0.01 Mantel-Cox log rank test; n = 45) <br />                                  (Figure 3A). As caffeine, inhibition DAF-16 (Figure 3B) or <br />                                  CBP-1 (Figure 3C) blocked effect tannic acid increase <br />                                  lifespan. As caffeine ciplopirox, tannic acid reduced <br />                                  age-related acceleration mortality rate, inhibition either <br />                                  CBP-1 DAF-16 prevented protective effect (Table 2). <br />                                  Tannic acid produced striking delay onset of <br />                                  pathology associated proteotoxicity, day 13, only <br />                                  15% control worms remained mobile compared 45% of <br />                                  worms treated tannic acid (P,0.01; n = 30) (Figure 3D). <br />                                  However, tannic acid 1% concentration significantly reduced <br />                                  lifespan. <br />  <br />  <br /> PLoS ONE | www.plosone.org   3                       November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                                                                               FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />  Table 2. Average G-value gathered maximum likely-hood                             Table 3. N2 Lifespan. <br />  estimates methods. <br />  <br />                                                                                       Drug                Mean       Sem +/2     Min         Max       Number (n) <br />                                                    a(x105)           g(X102) <br />                                                                                       Vehicle             21.31      0.58        11          27        45 <br />  N2 Vehicle (n = 45)                                 25.58            30.55           Caffeine            27.58      0.51        17          41        45 <br />  N2 Caffeine (n = 45)                               102.73            16.73*          CPX                 29.98      0.43        11          39        45 <br />  daf-16(RNAi) Vehicle (n = 32)                       34.96            40.83           Tannic acid         26.60      0.50        17          43        45 <br />  daf-16(RNAi) Caffeine (n = 20)                      1.71             56.89           Acetaminophen       31.67      0.43        23          47        45 <br />  cbp-1 (RNAi) Vehicle (n = 40)                       7.63             49.36           Bacitracin          33.78      0.37        17          47        45 <br />  cbp-1 (RNAi) Caffeine (n = 32)                      8.75             53.32           Baicalein           29.13      0.44        17          41        45 <br />  N2 Vehicle (n = 45)                                 25.58            30.55 <br />                                                                                       Lifespan C. elegans (N2) presence drugs administered optimal <br />  N2 CPX(n = 45)                                      24.59            20.27*          concentration. The average mean lifespan (in days) standard deviation <br />  daf-16(RNAi) Vehicle (n = 32)                       34.96            40.83           calculated experiments (45 total worms condition). Min Max <br />                                                                                       mark day (respectively) animal scored dead. <br />  daf-16(RNAi) CPX (n = 30)                           0.06             65.37* <br />                                                                                       doi:10.1371/journal.pone.0027762.t003 <br />  cbp-1 (RNAi) Vehicle (n = 40)                       7.64             49.36 <br />  cbp-1 (RNAi) CPX (n = 30)                           0.26             65.48          CBP-1 completely prevented protective effects acetamino- <br />  N2 Vehicle (n = 45)                                 25.58            30.55          phen (Figure 4C). Acetaminophen differed drugs <br />  N2 Tannic Acid (n = 45)                            152.53            16.26*         described extension lifespan associated <br />  daf-16(RNAi) Vehicle (n = 28)                       28.42            51.02 <br />                                                                                      reduction acceleration mortality rate standard <br />                                                                                      condition (Table 2). However, daf-16 inhibited <br />  daf-16(RNAi) Tannic Acid (n = 15)                   80.2             37.41 <br />                                                                                      acetaminophen significantly reduced acceleration mortality rate <br />  cbp-1 (RNAi) Vehicle (n = 26)                       32.74            58.39          (Table 2), supporting protective effect drug <br />  cbp-1 (RNAi) Tannic Acid (n = 24)                   14.11            71.84          independent DAF-16. In contrast, cbp-1 inhibited, <br />  N2 Vehicle (n = 45)                                115.72            18.66          acetaminophen increased mortality rate, again <br />  N2 Acetaminophen (n = 45)                           43.07            19.45          supporting protective effects acetaminophen depends <br />  daf-16(RNAi) Vehicle (n = 32)                       34.96            40.83 <br />                                                                                      CBP-1. However, acetaminophen failed delay onset of <br />                                                                                      pathology associated proteotoxicity. At higher concentra- <br />  daf-16(RNAi) Acetaminophen (n = 30)                270.76            19.38* <br />                                                                                      tion (1%) acetaminophen significantly reduced lifespan (not <br />  cbp-1 (RNAi) Vehicle (n = 40)                       7.64             49.36          shown). <br />  cbp-1 (RNAi) Acetaminophen (n = 45)                  0.6             63.51 <br />  N2 Vehicle (n = 45)                                115.72            18.66 <br />                                                                                      Bacitracin increases lifespan dependent CBP-1 and <br />  N2 Bacitracin (n = 45)                             104.29            16.09 <br />                                                                                      delays proteotoxcity <br />  daf-16(RNAi) Vehicle (n = 32)                       34.96            40.83              Bacitracin (1%), topical antibiotic, increased maximum <br />  daf-16(RNAi) Bacitracin (n = 35)                   265.53            20.20*         lifespan 74% (Table 3) significantly increased median <br />  cbp-1 (RNAi) Vehicle (n = 40)                       7.64             49.36          lifespan (Figure 5A) (P,0.01; n = 45). Inhibition DAF-16 <br />  cbp-1 (RNAi) Bacitracin (n = 46)                    4.22             56.53          reduced life-extending effect bacitracin did not <br />                                                                                      completely block (Figure 5B; p,0.01; n = 35). In contrast, <br />  N2 Vehicle (n = 45)                                 25.58            30.55 <br />                                                                                      inhibition cbp-1 completely blocked life-extending effect of <br />  N2 Bacailene (n = 45)                               68.57            17.34* <br />                                                                                      bacitracin (Figure 5C). Like acetaminophen, bacitracin increased <br />  daf-16(RNAi) Vehicle (n = 29)                        1.3             62.68          lifespan significantly reducing age-associated acceleration <br />  daf-16(RNAi) Bacailene (n = 28)                     44.9             35.08*         mortality rate (Table 2). However, bacitracin did reduce <br />  cbp-1 (RNAi) Vehicle (n = 29)                       2.98             58.53          acceleration mortality rate daf-16 inhibited (which <br />  cbp-1 (RNAi) Bacailene (n = 30)                     2.82              65.1          increased mortality rate), effect observed cbp-1 was <br />                                                                                      inhibited (Table 2). These results demonstrate the <br />  *Significant decrease values (as measured one-sided chi squared).             protective effects bacitracin independent DAF-16 but <br />  The relative rate aging measured Gompertz&#8217;s analysis. The change        dependent CBP-1. Bacitracin significantly delayed <br />  initial age- independent rate mortality relative vehicle treated <br />  controls (a). The change age-dependent mortality rate, Gompertz&#8217;s <br />                                                                                      pathology associated proteotoxicity (P.0.02; n = 30). <br />  variable (g) relation vehicle treated controls. <br />  doi:10.1371/journal.pone.0027762.t002                                               Baicalein increases lifespan slows aging dependent <br />                                                                                      CBP-1 does significantly delay proteotoxicity <br /> Acetaminophen increases lifespan dependent CBP-1                                      Baicalein (0.1%), anti-inflammatory component a <br /> and does delay proteotoxicty                                                     traditional Chinese herbal preparation [15], increased maximum <br />    Acetaminophen (0.01%), non-steroidal anti-inflammatory                          lifespan 52% significantly increased median lifespan <br /> drug, increased maximum lifespan 66% (Table 3)                                (Figure 6A; p,0.01; n = 45). Although inhibition DAF-16 <br /> significantly increased median lifespan (P,0.01; N = 45)                             substantially reduced protective effects baicalein, drug <br /> (Figure 4A). Inhibition DAF-16 did prevent effect                      significantly increased lifespan daf-16 inhibited by <br /> acetaminophen increase lifespan (Figure 4B), inhibition                    RNAi (Figure 6B; p = 0.01; n = 28). In contrast cbp-1 RNAi <br />  <br />  <br />  <br />  <br />        PLoS ONE | www.plosone.org                                                4                         November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                         FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                  Figure 2. Ciclopirox olamine increases N2 longevity CBP-1 <br />                                  DAF-16 independent, manner fails rescue A-beta <br />                                  toxicity. A. N2 longevity increased .01% ciclopirox olamine vs. <br />                                  vehicle (P,0.01). B. Survival daf-16 (RNAi) increased .01% <br />                                  ciclopirox olamine vs. vehicle (P,0.01). C. Survival cbp-1 (RNAi) is <br />                                  increased .01% ciclopirox olamine vs. untreated control (P,.01). D. <br />                                  Survival Abeta Tg unchanged .01% ciclopirox olamine vs. <br />                                  vehicle. <br />                                  doi:10.1371/journal.pone.0027762.g002 <br />  <br />  <br />  <br />                                  completely blocked increase lifespan produced baicalein <br />                                  (Figure 6C). Interestingly, baicalein protects against <br />                                  Abeta toxicity mammalian neurons [16], concentration <br />                                  extended lifespan compound did significantly reduce <br />                                  pathology associated Abeta proteotoxicity C. elegans <br />                                  (Figure 6D). <br />  <br />                                  Discussion <br />                                      In present studies 1.5% drugs screened protected <br />                                  glucose toxicity striking 23% drugs <br />                                  significantly increased lifespan. By comparison, unbiased <br />                                  screen 88,000 compounds, 0.13% drugs increased <br />                                  lifespan (half increased lifespan 10%). Of the <br />                                  drugs increased lifespan, 86% slowed rate aging, as <br />                                  indicated analysis mortality rate statistics [17] using a <br />                                  recently validated algorithm [18]. Inhibition cbp-1blocked the <br />                                  protective effects drugs aging just inhibits <br />                                  protective effects dietary restriction (but cold) [6]. In <br />                                  contrast protective effects were <br />                                  dependent DAF-16, just protective effects some <br />                                  methods dietary restriction dependent DAF-16 [6,19]. <br />                                  These observations consistent evidence glucose <br />                                  metabolism toxicity play prominent role driving aging <br />                                  process [7,8,20], does diabetic complications [13]. Similarly <br />                                  studies support reduction glucose toxicity mediates <br />                                  protective effects dietary restriction aging dependent on <br />                                  activity Cbp [6]. <br />                                      The present studies began blinded screen the <br />                                  Spectrum Collection (Microsource) potential protective effects <br />                                  glucose toxicity mammalian neuron for <br />                                  potential use prevent reverse complications diabetes. <br />                                  Similar screens library compounds, have <br />                                  known safety profiles use humans, led potential <br />                                  repositioning therapeutic drugs known safety profiles for <br />                                  novel therapeutic purposes [11]. A major consideration when <br />                                  carrying screens challenge obtaining the <br />                                  optimally protective dose, protective compounds are <br />                                  generally toxic higher doses. Indeed observed initial <br />                                  screen mammalian neurons screening concentration <br />                                  drugs fact toxic. Therefore screened three <br />                                  concentrations C. elegans drugs the <br />                                  highest concentration examined (1%) reduced lifespan, at <br />                                  lower concentrations drugs increased lifespan. A related <br />                                  concern extent protective concentrations <br />                                  observed C. elegans study, compounds were <br />                                  added environment, translate doses safe to <br />                                  use humans mammals. In present study we <br />                                  screened concentrations 0.01 1% (roughly 100 uM to <br />                                  10 mM) medium concentrations often <br />                                  produce similar effects C. elegans produced therapeutic <br />                                  doses humans (e.g., fluoxetine [21]), course not <br />                                  clear precisely tissue concentration drug the <br />                                  worm conditions. <br />  <br />  <br /> PLoS ONE | www.plosone.org   5                       November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                         FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                  Figure 3. Tannic acid increases N2 longevity CBP-1 and <br />                                  DAF-16 dependent, manner reduces Abeta toxicity. A. N2 <br />                                  longevity increased .01% tannic acid vs. vehicle (P,0.01). B. <br />                                  Survival daf-16 (RNAi) unchanged .01% tannic acid vs. vehicle. <br />                                  C. Survival cbp-1 (RNAi) unchanged .01% tannic acid vs. <br />                                  untreated control. D. Survival A-beta Tg increased .01% tannic <br />                                  acid vs. vehicle (P = 0.01). <br />                                  doi:10.1371/journal.pone.0027762.g003 <br />  <br />  <br />  <br />                                     Since safety profile protective drugs known in <br />                                  cases mechanisms protective action studied, <br />                                  make promising lead compounds treat age-related diseases <br />                                  including diabetes Alzheimer&#8217;s disease. Thus caffeine <br />                                  (ED50 = 12 mg/kg; LD50 = 200 mg/kg) effective 0.1% <br />                                  concentration (5.1 mM) increase lifespan reduce proteo- <br />                                  toxicity, corroborating similar result 3.6 mM caffeine added <br />                                  medium reduced pathology transgenic model of <br />                                  proteotoxicity associated Alzheimer&#8217;s disease [22]. Many <br />                                  epidemiological studies observed consumption coffee <br />                                  caffeinated drinks appears highly protective <br />                                  variety pathologies including Parkinson&#8217;s disease [23] <br />                                  Alzheimer&#8217;s disease [24]. Similarly, administration caffeine <br />                                  experimental models diseases protective [25]. Many <br />                                  mechanisms suggested mediate protective <br />                                  effects caffeine, established [24]. <br />                                     Ciclopirox used clinically topical antifungal agent an <br />                                  ED50 oral doses known. However, LD50 oral <br />                                  doses 2000 mg/kg (e.g., 10-fold higher caffeine) <br />                                  protective concentration 10-fold lower for <br />                                  caffeine. Interestingly ciclopirox protects PC12 neuronal cells from <br />                                  cell death removal trophic support [26], protects <br />                                  astrocytes peroxynitrate toxicity maintaining mitochon- <br />                                  drial function, unknown mechanisms. Tannic acid also <br />                                  exhibits LD50 2000 mg/kg protects neurons [27] <br />                                  produces protective effects; many <br />                                  mechanisms suggested, established <br />                                  [28]. Interestingly acetaminophen (LD50 1000 mg/kg) <br />                                  protects neurons brain endothelial cells oxidative <br />                                  stress mechanism entail inhibition apoptosis <br />                                  [29,30]. Bacitracin (LD50 1000 mg/kg) topical <br />                                  antibiotic appears specifically inhibit cholinesterases <br />                                  associated plaques tangles Alzheimer&#8217;s disease [31]. <br />                                  Although antibiotic, mechanism bacitracin <br />                                  increases lifespan probably mediated dietary restriction <br />                                  secondary reduced bacterial growth, dietary restriction <br />                                  reduces rate aging C. elegans [9] bacitracin did not <br />                                  reduce rate aging (Table 2). Baicalein anti- <br />                                  inflammatory flavanoid isolated traditional Chinese <br />                                  herbal preparation known hua&#180;ng q&#305;&#180;n (derived <span id='am-31' about='obo:NCBITaxon_4139' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_216702 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_4136 obo:NCBITaxon_4143 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91888 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71274 obo:NCBITaxon_3193'><span id='am-32' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-34' property="rdfs:label" content="Scutellaria" datatype="xsd:string"></span><span id='am-35'  ></span>Scutellaria</span> <br />                                  baicalensis) shown protect neurons beta- <br />                                  amyloid toxicity [16] insults including ischemic stroke <br />                                  [32] unknown mechanisms. <br />                                     Thus compounds discovered screen been <br />                                  shown neuroprotective various circumstances the <br />                                  clear common denominator mechanisms which <br />                                  diverse compounds exert protective effects remain <br />                                  unclear. It particular protective <br />                                  effects of compounds blocked inhibition cbp-1 <br />                                  RNAi similar inhibition daf-16 blocked <br />                                  protective effects 2 compounds. Since RNAi does not <br />                                  completely block expression DAF-16 cells does not <br />                                  rule DAF-16 plays role mediating these <br />                                  protective effects. Nevertheless evidence clearly supports a <br />  <br />  <br /> PLoS ONE | www.plosone.org   6                        November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                                                                    FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                                                              control. D. Survival Abeta Tg unchanged 0.1% acetaminophen <br />                                                                              vs. vehicle. <br />                                                                              doi:10.1371/journal.pone.0027762.g004 <br />  <br />  <br />  <br />  <br />                                                                              robust role CBP-1 DAF-16 mediating <br />                                                                              protective effects drugs does protocols of <br />                                                                              dietary restriction [6]. Since protective effects drugs <br />                                                                              based screen neuroprotection glucose toxicity, <br />                                                                              CBP-1 appears particularly protective [6], <br />                                                                              probably coincidence protective effects these <br />                                                                              drugs largely dependent CBP-1. On hand <br />                                                                              5 6 drugs reduce rate aging mimic the <br />                                                                              effects dietary restriction (caffeine, ciclopirox, tannic acid, <br />                                                                              baicalein and, daf-16 inhibited, bacitracin acetamin- <br />                                                                              ophen). Similarly 3 6 drugs delayed pathology a <br />                                                                              model proteotoxicity associated Alzheimer&#8217;s disease <br />                                                                              (caffeine, bacitracin, tannic acid), 3 did not. Thus, the <br />                                                                              protective effects drugs appear depend CBP-1, <br />                                                                              apparently differences mechanisms mediating <br />                                                                              protective effects drugs. <br />                                                                                  In conclusion present studies demonstrate drugs which <br />                                                                              protect glucose toxicity exhibit remarkably high <br />                                                                              probability increasing lifespan reducing proteotoxicity. <br />                                                                              Furthermore protective effects, like protective effects of <br />                                                                              dietary restriction DAF-16, highly dependent the <br />                                                                              transcriptional factor CBP-1, so, DAF-16. <br />                                                                              Finally, present studies greatly extend number of <br />                                                                              corroborated drugs protect wide range of <br />                                                                              age-related pathologies including diabetic complications, Alzhei- <br />                                                                              mer&#8217;s disease, rate aging itself. <br />  <br />                                                                              Methods <br />                                                                              C. elegans strains <br />                                                                                 All strains obtained <span id='am-48' about='obo:NCBITaxon_6237' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-49' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-50' property="rdfs:label" content="Caenorhabditis" datatype="xsd:string"></span><span id='am-51'  ></span><span id='am-52' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Caenorhabditis</span> Genetics <br />                                                                              Center, funded NIH National Center Research <br />                                                                              Resources (NCRR), maintained 20u C, standard <br />                                                                              conditions [33]. Strain CL2006, dvIs2[pCL12(unc-54/human Abeta <br />                                                                              peptide 1-42 minigene) + pRF4], used model proteotoxicity in <br />                                                                              Alzheimer&#8217;s disease, created Chris Link [12]. <br />  <br />                                                                              Drug screen <br />                                                                                 The initial drug screen compound library based on <br />                                                                              Spectrum Collection (Microsource), prepared coded by <br />                                                                              Juvenile Diabetes Research Foundation. The screen entailed <br />                                                                              assessing viability primary (E16) cortical neurons 1-hour <br />                                                                              exposure low dose (30 uM) hydrogen peroxide, using two <br />                                                                              distinct 96-well-based assays neuronal viability. In contrast to <br />                                                                              vitro models hyperglycemia, direct toxic <br />                                                                              effects extremely high, non-physiological (often 30 mM) <br />                                                                              levels glucose, 15 mM glucose did directly reduce neuronal <br />                                                                              viability, compared 5 mM glucose. However, brief <br />                                                                              exposure 100 uM hydrogen peroxide (determined dose- <br />                                                                              response curve), incubation 15 mM glucose reduced neuronal <br />                                                                              viability 24 hours later 75%, compared 5 mM glucose. <br />                                                                              Twenty-four hours later, medium removed stored for <br />                                                                              subsequent assay lactate dehydrogenase (Promega), viability <br /> Figure 4. Acetaminophen increases N2 longevity CBP-1                    assay (CKK-8; Dojindo Molecular Technologies). The wells were <br /> dependent, DAF-16 independent, manner fails to <br />                                                                              incubated read ELISA reader 450 nm, according to <br /> rescue Abeta toxicity. A. N2 longevity increased 0.1% <br /> acetaminophen vs. vehicle (P,0.01). B. Survival daf-16 (RNAi)          manufacturer&#8217;s instructions. Any drug producing statistically <br /> increased 0.1% acetaminophen vs. vehicle (P,0.01). C. Survival       significant increase cell viability CCK-8 assay (n = 8 <br /> cbp-1 (RNAi) unchanged 0.1% acetaminophen vs. untreated              cells/drug 15 mM glucose/100 uM hydrogen peroxide) re- <br />  <br />  <br />        PLoS ONE | www.plosone.org                                        7                      November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                          FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                  Figure 5. Bacitracin increases N2 longevity CBP-1 <br />                                  dependent DAF-16 independent, manner reduces <br />                                  Abeta toxicity. A. N2 longevity increased 01% bacitracin vs. <br />                                  vehicle (P,0.01). B. Survival daf-16 (RNAi) increased 01% <br />                                  bacitracin vs. vehicle (P = 0.01). C. Survival cbp-1 (RNAi) unchanged <br />                                  01% bacitracin vs. untreated control. D. Survival Abeta Tg is <br />                                  increased 01% bacitracin vs. vehicle (P,0.02). <br />                                  doi:10.1371/journal.pone.0027762.g005 <br />  <br />  <br />  <br />                                  screened using LDH assay subsequent replicate <br />                                  CCK-8 assay dose-response curves. Following screen in <br />                                  primary cortical neurons drugs used C. elegans screens <br />                                  (caffeine, ciclopirox olamine, tannic acid, acetaminophen, baica- <br />                                  lein, bacitracin) obtained Sigma. Drug treatment <br />                                  C. elegans entailed adding 400 ul solution containing either <br />                                  0.01%, 0.1%, 1% (by weight) designated drug, dissolved <br />                                  50% ethanol water, 10ml solidified agar 6 cm petri <br />                                  dish. Controls agar plates treated 50% ethanol water <br />                                  (vehicle). All drugs added overnight incubation 37uC <br />                                  bacterial strains: OP50, L4440 RNAi cassette the <br />                                  gene interest, L4440 (empty RNAi vector). <br />  <br />                                  Phenotypic assessment <br />                                      Worms scored day starting day 3 of <br />                                  adulthood. Survival assayed prodding worms a <br />                                  platinum wire observing movement. Lack movement was <br />                                  scored death, following worm removed <br />                                  plate. Scoring continued worms deceased. <br />                                  All studies carried experimenter blind the <br />                                  conditions (drugs RNAi constructs) tested. Further- <br />                                  more, results corroborated 3 separate lifespan <br />                                  curves. Several drugs reported significantly increased <br />                                  lifespan studies drugs reported here <br />                                  significantly increased lifespan 3 separate lifespan <br />                                  studies. <br />                                      In CL2006 model proteotoxicity associated with <br />                                  Alzheimer&#8217;s disease [12], worms scored daily paralysis <br />                                  starting day 1 adult day 12&#8211;13 point or <br />                                  worms died b-amyloid induced toxicity. <br />                                  Since comparison moribund paralyzed becomes <br />                                  unreliable mortality rate increases, stopped scoring <br />                                  mortality exceeded 50%. In initial screens worms were <br />                                  scored paralyzed failed respond prodding the <br />                                  posterior portion body moved head or <br />                                  pharynx dead movement observed. Since both <br />                                  paralysis shortened lifespan A-beta toxicity, <br />                                  subsequent screens simply treated paralyzed dead animals <br />                                  same. Nevertheless, scoring stopped , 50% survival <br />                                  maintain consistency. All scoring performed blind the <br />                                  drugs tested. <br />  <br />                                  RNAi <br />                                    In studies daf-16 cbp-1 inhibited using RNAi <br />                                  feeding C. elegans bacteria containing dsRNA constructs <br />                                  complementary targeted genes [34]. The bacteria <br />                                  expressing double-stranded RNAi constructs from <br />                                  Source Bioscience. <br />  <br />                                  Statistics <br />                                     Statistical significance effects lifespan determined <br />                                  using Kaplan-Meier test survivorship log- <br />                                  rank Mantel-Cox test median lifespan, implemented in <br />                                  Prism 4. Statistical significance effects age-dependent <br />  <br />  <br /> PLoS ONE | www.plosone.org   8                        November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                           FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br />                                  Figure 6. Baicalein increases N2 longevity CBP-1 depen- <br />                                  dent DAF-16 independent, manner fails rescue <br />                                  Abeta toxicity. A. N2 longevity increased 0.1% baicalein vs. <br />                                  vehicle (P,0.01). B. Survival daf-16 (RNAi) increased 0.1% <br />                                  baicalein vs. vehicle (P = 0.01). C. Survival cbp-1 (RNAi) reduced with <br />                                  0.1% baicalein vs. untreated control (P,0.01). D. Survival Abeta Tg is <br />                                  unchanged 0.1% baicalein vs. vehicle. <br />                                  doi:10.1371/journal.pone.0027762.g006 <br />  <br />  <br />  <br />  <br />                                  acceleration mortality rate measure rate aging [17] <br />                                  determined using maximum-likelihood method implement- <br />                                  ed R, extensively validated [9,18,35]. Of <br />                                  particular relevance, validated method demonstrating <br />                                  predicts maximal lifespan, 50% survival time, variance in <br />                                  control groups distribution deaths better standard the <br />                                  standard log-linear regression analysis, actual values <br />                                  A G similar computed method <br />                                  [18]. Because increased power algorithm, possible <br />                                  estimate age-associated acceleration mortality rate (G) and <br />                                  initial mortality rate (A) using survival curves substantially <br />                                  fewer individuals previously required [18]. One reason <br />                                  MLE provides substantially power log-linear <br />                                  regression unduly influenced mortality rates <br />                                  extremes lifespan, especially maximum lifespan <br />                                  [18]. Similarly, mean lifespan sensitive median <br />                                  lifespan extremes lifespan, standard survival curve <br />                                  statistics, including log-rank Mantel-Cox, based the <br />                                  median mean lifespan. Nevertheless, many <br />                                  studies report mean lifespan, include estimates the <br />                                  proposed studies well. <br />  <br />  <br />                                  Supporting information <br />                                     Multiple drug screens performed determine both <br />                                  efficacy optimal concentration drugs recovered from <br />                                  FDA approved drug library. Primary screens C. elegans <br />                                  elucidated 6 drugs capable protecting amyloid <br />                                  induced toxicity, enhancing lifespan, (figure S1). <br />                                  Significant increases lifespan observed caffeine, <br />                                  CPX, tannic acid, acetaminophen, bacitracin (p = , .05 <br />                                  measured Mantel-Cox). Baicalein did yield significant <br />                                  differences experiment. However, treatment with <br />                                  baicalein trends increase lifespan. Further, the <br />                                  small sample size (n = 15) likely obscures significant <br />                                  increase, increases lifespan observed several <br />                                  studies (data shown). <br />  <br />                                  Supporting Information <br />                                  Figure S1 Survival curves seven FDA approved drugs <br />                                  discovered protective C. elegans screen. <br />                                  Lifespan extension observed caffeine A. Lifespan extension <br />                                  observed Ciclopirox olamine (B). Lifespan extension <br />                                  produced tannic acid (C). Lifespan extension produced by <br />                                  acetaminophen (D). Lifespan extension observed bacitracin <br />                                  (E). Lifespan extension observed baicalein (F). <br />                                  (TIF) <br />  <br />                                  Author Contributions <br />                                  Conceived designed experiments: AL FI CM. Performed the <br />                                  experiments: AL FI HP LN DH MS. Analyzed data: AL FI KY CM. <br />                                  Contributed reagents/materials/analysis tools: AL KY CM. Wrote the <br />                                  paper: AL CM. <br />  <br />  <br /> PLoS ONE | www.plosone.org   9                         November 2011 | Volume 6 | Issue 11 | e27762 <br />                                                                                                                          FDA-Approved Drugs Protect Aging <br />  <br />  <br />  <br /> References <br />  1. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin                    19. Greer EL, Brunet A (2009) Different dietary restriction regimens extend lifespan <br />     activators mimic caloric restriction delay ageing metazoans. Nature 430:               independent overlapping genetic pathways C. elegans. Aging Cell <br />     686&#8211;689.                                                                                      8: 113&#8211;127. <br />  2. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K (2005) Anticonvulsant                   20. Lin SJ, Defossez PA, Guarente L (2000) Requirement NAD SIR2 life- <br />     medications extend worm life-span. Science 307: 258&#8211;262.                                      span extension calorie restriction <span id='am-7' about='obo:NCBITaxon_4932' typeof='owl:Thing obo:NCBITaxon_4930 obo:NCBITaxon_1 obo:NCBITaxon_4751 obo:NCBITaxon_131567 obo:NCBITaxon_4893 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_4892 obo:NCBITaxon_4891 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_147537 obo:NCBITaxon_2759'><span id='am-8' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces capensis" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-10'  ></span><span id='am-11' property="oboInOwl:hasExactSynonym" content="lager beer yeast" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces uvarum var. melibiosus" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasExactSynonym" content="baker&apos;s yeast" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasRelatedSynonym" content="Saccaromyces cerevisiae" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasExactSynonym" content="brewer&apos;s yeast" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces italicus" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="Saccharomyces cerevisiae" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasRelatedSynonym" content="Candida robusta" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasRelatedSynonym" content="Saccharomyes cerevisiae" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasRelatedSynonym" content="Sccharomyces cerevisiae" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces oviformis" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasExactSynonym" content="yeast" datatype="xsd:string"></span>Saccharomyces cerevisiae</span>. Science 289: <br />  3. Petrascheck M, Ye X, Buck LB (2007) An antidepressant extends lifespan                2126&#8211;2128. <br />     adult <span id='am-41' about='obo:NCBITaxon_6239' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6237 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-42' property="oboInOwl:hasExactSynonym" content="roundworm" datatype="xsd:string"></span><span id='am-43' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-45'  ></span><span id='am-46' property="oboInOwl:hasRelatedSynonym" content="Rhabditis elegans" datatype="xsd:string"></span><span id='am-47' property="rdfs:label" content="Caenorhabditis elegans" datatype="xsd:string"></span>Caenorhabditis elegans</span>. Nature 450: 553&#8211;556.                                        21. Kullyev A, Dempsey CM, Miller S, Kuan CJ, Hapiak VM, et al. (2010) A <br />  4. Jia K, Chen D, Riddle DL (2004) The TOR pathway interacts insulin                    genetic survey fluoxetine action synaptic transmission Caenorhabditis <br />     signaling pathway regulate C. elegans larval development, metabolism life              elegans. Genetics 186: 929&#8211;941. <br />     span. Development 131: 3897&#8211;3906.                                                         22. Dostal V, Roberts CM, Link CD (2010) Genetic Mechanisms Coffee Extract <br />  5. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, et al. (2009)                           Protection Caenorhabditis elegans Model {beta}-Amyloid Peptide <br />     Rapamycin fed late life extends lifespan genetically heterogeneous mice.                Toxicity. Genetics 186: 857&#8211;866. <br />     Nature 460: 392&#8211;395.                                                                      23. Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010) Caffeine exposure <br />  6. Zhang M, Poplawski M, Yen K, Cheng H, Bloss E, et al. (2009) Role CBP <br />                                                                                                   risk Parkinson&#8217;s disease: systematic review <span id='am-58' about='obo:NCBITaxon_94025' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_27394 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_74971 obo:NCBITaxon_74974 obo:NCBITaxon_6854 obo:NCBITaxon_6843 obo:NCBITaxon_74975 obo:NCBITaxon_33154 obo:NCBITaxon_6905 obo:NCBITaxon_6656 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6893 obo:NCBITaxon_6072'><span id='am-59' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-60' property="rdfs:label" content="Meta" datatype="xsd:string"></span><span id='am-61'  ></span><span id='am-62' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>meta</span>-analysis of <br />     SATB-1 aging, dietary restriction, insulin-like signaling. PLoS Biol 7: <br />                                                                                                   observational studies. J Alzheimers Dis 20(Suppl 1): S221&#8211;238. <br />     e1000245. <br />                                                                             <br /> </body></html>